IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody

IDH1 R132H
IDH1 R132H (MRQ-67) on Astrocytoma

IDH1 R132H (MRQ-67) Rabbit Monoclonal Antibody

Specialties: Anatomic Pathology Hematopathology Neuropathology

Updated: 2021-05-19 13:20:18

Isocitrate dehydrogenase 1 (IDH1) functions as an enzyme in the Krebs (citric acid) cycle and is biologically active in the cytoplasmic and peroxisomal compartments under normal conditions.  The occurrence of heterozygous missense mutations at an arginine residue at codon 132 (R132) within the coding region for the substrate binding site of IDH1 has been described to promote oncogenesis in several malignancies.1 Of the identified mutant variants, a histidine substitution (R132H) is one of the more frequently observed point mutations in certain tumor groups of gliomas.2 Mutations involving IDH1 have been implicated as early events during gliomagenesis and IDH1 mutation status was incorporated into the 2016 WHO Classification of Tumors of the Central Nervous System as a new parameter for sub-classifying diffuse astrocytic and oligodendrogliomal tumors.3,4 Immunohistochemical identification of IDH1 R132H immunoreactivity can be used as a tool in screening tumors that may be harboring this mutation, such as low grade diffuse and anaplastic astrocytomas, oligodendrogliomas, and secondary glioblastomas.

  1. Yang, H, et al. IDH1 and IDH2 mutations in tumorigenesis: mechanistic insights and clinical perspectives. Clin Cancer Res. 2012; 18:5562-5571.
  2. Balss, J, et al. Analysis of the IDH1 codon 132 mutation in brain tumors. Acta Neuropathol. 2008; 116:597–602.
  3. Watanabe, T, et al. IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am. J. Pathol. 2009; 174:1149-1153.
  4. Louis, D.N., et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: A summary. Acta Neuropathol. 2016; 131:803-820.

Specifications


  • Reactivity: paraffin
  • Control: Astrocytoma (Cytoplasmic); Oligodendroglioma (Cytoplasmic); Glioblastoma (Cytoplasmic); Acute myeloid leukemia (Cytoplasmic)
  • Dilution Range: 1:25-1:100 *

Package Inserts


IFU SDS
Learn how to obtain your SDS

Ordering Information

For in vitro diagnostic (IVD) use in USA

0.1 mL concentrate456R-34
0.5 mL concentrate456R-35
1.0 mL concentrate456R-36
1.0 mL predilute ready-to-use456R-37
7.0 mL predilute ready-to-use456R-38

This product is not available in Canada

For in vitro diagnostic (IVD) use in Europe

0.1 mL concentrate456R-34
0.5 mL concentrate456R-35
1.0 mL concentrate456R-36
1.0 mL predilute ready-to-use456R-37
7.0 mL predilute ready-to-use456R-38

This product is not available in Japan

 

To request information on this product in additional countries, please click the button below.

Request More Information